[Click e-Stock] "Now Is the Time to Buy... Seegene Sees New Products and Businesses Materialize"
On April 1, Daol Investment & Securities announced that it is maintaining its “Buy” investment opinion and a target price of 35,000 won for Seegene.
Jonghyun Park, a researcher at Daol Investment & Securities, stated, “Long-term accumulated research and development (R&D) investments are now materializing into new products and new businesses.” He analyzed, “We see the current moment, where momentum for earnings improvement and cost leverage are occurring simultaneously, as a buying opportunity.”
He added, “Seegene’s revenue for the first quarter of this year is expected to exceed forecasts at 129.1 billion won, with operating profit expected at 15 billion won.” He continued, “Driven by strong performance in respiratory virus (RV) and respiratory bacteria (PB) products, respiratory sales are expected to reach 34.2 billion won, while gastrointestinal (GI) sales remain solid, bringing total sales to an estimated 55.2 billion won.”
For the full year, revenue and operating profit are projected to rise by 14% and 58%, respectively, compared to the same period last year, reaching 540.7 billion won and 54.8 billion won. Park noted, “In the second half of this year, a new product developed through open innovation with Springer Nature is scheduled for launch, with the first product targeting multidrug-resistant organisms (MDRO) and the product lineup within the healthcare-associated infection (HAI) domain already finalized.”
Park also stated, “Pilot services for new businesses such as STAgora, a diagnostic data platform, and CURECA, an unmanned molecular diagnostic system, will be launched in the second half of this year, which is expected to create operating leverage through reduced R&D expenses.” He added, “Commercialization is likely to occur after 2027.”
He went on to say, “With automated preprocessing through CURECA, the introduction of PCR, which has been the slowest in the gastrointestinal and circulatory systems, is now anticipated.”
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
There is also the issue of treasury share cancellation. Park said, “Seegene plans to cancel 5.49 million treasury shares, excluding those held for disposal or compensation purposes. If all treasury shares intended for cancellation are retired, CEO Chun Jongyun’s shareholding will be 20.3%, and 32.3% when including related parties.” He continued, “The quarterly dividend of 200 won per share is expected to be maintained, resulting in a dividend yield of 3.7%.”
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.